Yuran Qiu

619 total citations
14 papers, 505 citations indexed

About

Yuran Qiu is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Yuran Qiu has authored 14 papers receiving a total of 505 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Yuran Qiu's work include Lymphoma Diagnosis and Treatment (4 papers), Chemical Synthesis and Analysis (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Yuran Qiu is often cited by papers focused on Lymphoma Diagnosis and Treatment (4 papers), Chemical Synthesis and Analysis (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). Yuran Qiu collaborates with scholars based in China, Australia and Thailand. Yuran Qiu's co-authors include Shaoyong Lu, Jian Zhang, Jun Pu, Duan Ni, Xinheng He, Xinyi Li, Jiacheng Wei, Yuanhao Wang, Ashfaq Ur Rehman and Yun Li and has published in prestigious journals such as Blood, Trends in Pharmacological Sciences and Molecules.

In The Last Decade

Yuran Qiu

12 papers receiving 502 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Yuran Qiu China	9	418	148	59	53	47	14	505
Vivek Modi United States	9	494 1.2×	156 1.1×	98 1.7×	45 0.8×	113 2.4×	12	643
Oscar P. J. van Linden Netherlands	5	272 0.7×	162 1.1×	87 1.5×	29 0.5×	31 0.7×	7	379
Matteo Rossi Sebastiano Italy	14	460 1.1×	78 0.5×	143 2.4×	51 1.0×	24 0.5×	21	610
Jiacheng Wei China	8	269 0.6×	88 0.6×	60 1.0×	23 0.4×	25 0.5×	10	364
Laura A. Lopez-Garcia Germany	13	517 1.2×	66 0.4×	73 1.2×	55 1.0×	35 0.7×	16	629
Saliha Ece Acuner Türkiye	8	336 0.8×	85 0.6×	51 0.9×	19 0.4×	55 1.2×	10	456
Michael Smolinski United States	10	318 0.8×	156 1.1×	122 2.1×	16 0.3×	59 1.3×	18	504
Alexander Gozman United States	8	612 1.5×	139 0.9×	120 2.0×	52 1.0×	54 1.1×	22	778
Georgi K. Kanev Netherlands	6	292 0.7×	144 1.0×	53 0.9×	13 0.2×	27 0.6×	7	366
Susan L. Gloor United States	15	463 1.1×	89 0.6×	62 1.1×	18 0.3×	27 0.6×	21	643

Countries citing papers authored by Yuran Qiu

Since Specialization

Citations

This map shows the geographic impact of Yuran Qiu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Yuran Qiu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Yuran Qiu more than expected).

Fields of papers citing papers by Yuran Qiu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Yuran Qiu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Yuran Qiu. The network helps show where Yuran Qiu may publish in the future.

Co-authorship network of co-authors of Yuran Qiu

This figure shows the co-authorship network connecting the top 25 collaborators of Yuran Qiu. A scholar is included among the top collaborators of Yuran Qiu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Yuran Qiu. Yuran Qiu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

14 of 14 papers shown

Qiu, Yuran, et al.. (2025). Golidocitinib combined with CHOP in treatment-Naïve monomorphic epitheliotropic intestinal T-cell lymphoma: Preliminary results from A phase 2 multicenter, single-arm goal study. Blood. 146(Supplement 1). 3649–3649.

Qiu, Yuran, Kun Cai, Shu Cheng, et al.. (2025). DDX3X mutation and Epstein-Barr virus cooperate to induce R-loop-dependent oncogenesis. Cell Reports. 44(9). 116237–116237.

Huang, Yao‐Hui, Yuran Qiu, Qunling Zhang, et al.. (2024). Genomic and transcriptomic profiling of peripheral T cell lymphoma reveals distinct molecular and microenvironment subtypes. Cell Reports Medicine. 5(2). 101416–101416. 8 indexed citations

Qiu, Yuran & Weili Zhao. (2024). Precise diagnosis and treatment for peripheral T-cell lymphomas: From pathogenic mechanisms to innovative approaches. 2(1). 100048–100048. 1 indexed citations

Liu, Qing, et al.. (2023). Cardiovascular toxicity of tyrosine kinase inhibitors during cancer treatment: Potential involvement of TRPM7. Frontiers in Cardiovascular Medicine. 10. 1002438–1002438. 7 indexed citations

Zhang, Qiufen, Yingyi Chen, Duan Ni, et al.. (2021). Targeting a cryptic allosteric site of SIRT6 with small-molecule inhibitors that inhibit the migration of pancreatic cancer cells. Acta Pharmaceutica Sinica B. 12(2). 876–889. 52 indexed citations

Wang, Yuanhao, Yingfei Chen, Yuran Qiu, et al.. (2021). Mechanistic insights into the effect of phosphorylation on Ras conformational dynamics and its interactions with cell signaling proteins. Computational and Structural Biotechnology Journal. 19. 1184–1199. 60 indexed citations

Qiu, Yuran, Yuanhao Wang, Zong‐Tao Chai, et al.. (2021). Targeting RAS phosphorylation in cancer therapy: Mechanisms and modulators. Acta Pharmaceutica Sinica B. 11(11). 3433–3446. 26 indexed citations

Qiu, Yuran, Xiaolan Yin, Xinyi Li, et al.. (2021). Untangling Dual-Targeting Therapeutic Mechanism of Epidermal Growth Factor Receptor (EGFR) Based on Reversed Allosteric Communication. Pharmaceutics. 13(5). 747–747. 47 indexed citations

10.

He, Xinheng, Yuran Qiu, Jian Zhang, et al.. (2021). Conformational Selection Mechanism Provides Structural Insights into the Optimization of APC-Asef Inhibitors. Molecules. 26(4). 962–962. 13 indexed citations

11.

Ni, Duan, Jiacheng Wei, Xinheng He, et al.. (2020). Discovery of cryptic allosteric sites using reversed allosteric communication by a combined computational and experimental strategy. Chemical Science. 12(1). 464–476. 108 indexed citations

12.

Ni, Duan, Yun Li, Yuran Qiu, et al.. (2020). Combining Allosteric and Orthosteric Drugs to Overcome Drug Resistance. Trends in Pharmacological Sciences. 41(5). 336–348. 74 indexed citations

13.

Qiu, Yuran, Xinyi Li, Xinheng He, et al.. (2020). Computational methods-guided design of modulators targeting protein-protein interactions (PPIs). European Journal of Medicinal Chemistry. 207. 112764–112764. 31 indexed citations

14.

Lu, Shaoyong, Yuran Qiu, Duan Ni, et al.. (2019). Emergence of allosteric drug-resistance mutations: new challenges for allosteric drug discovery. Drug Discovery Today. 25(1). 177–184. 78 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact